SCHEDULE: Nantahala Capital Reduces VistaGen Stake to 4.71%

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a beneficial ownership of 4.71% in VistaGen Therapeutics, Inc. as of December 31, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (the "Reporting Persons") collectively hold 1,953,045 shares of VistaGen Therapeutics, Inc. Common Stock.
• This aggregate amount represents 4.71% of the total outstanding shares of VistaGen Therapeutics, Inc. as of December 31, 2025.
• The Reporting Persons share both voting and dispositive power over all 1,953,045 shares.
• Nantahala Capital Management, LLC is a Massachusetts limited liability company, while Messrs. Harkey and Mack are U.S. citizens.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal, as a reduction in a significant institutional stake, particularly below the 5% threshold, often implies a diminished conviction or reallocation of capital by the investor.

Negatives

• The filing indicates a reduction in beneficial ownership from a previous filing (Amendment No. 3 implies prior filings with higher ownership), falling below the 5% threshold for mandatory disclosure of significant ownership changes, which could be interpreted as a decrease in conviction by the reporting entity.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding VistaGen Therapeutics, Inc.'s future performance or strategic direction.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive investors who own more than 5% but less than 20% of a company's stock, or who have reduced their stake below 5%. For a biotechnology company like VistaGen Therapeutics, changes in institutional ownership can sometimes signal shifts in investor sentiment, though this specific filing is a standard disclosure of a reduced stake.

Stakeholder Impact

• Shareholders: May interpret the reduction in institutional ownership as a signal of decreased confidence from a notable investor, potentially influencing their own investment decisions.

Key Dates

Recommendation

While the reduction in a significant institutional stake to below 5% is a negative signal, a Schedule 13G filing primarily reports ownership changes rather than fundamental company performance. Without additional context on VistaGen Therapeutics' operational or financial updates, a 'hold' recommendation is appropriate, advising investors to monitor future developments and other financial disclosures before making a definitive buy or sell decision.

Keywords

VistaGen Therapeutics, Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals